Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Eiji Torikai"'
Autor:
Mochihito Suzuki, Shuji Asai, Ryota Hara, Yuji Hirano, Satomi Nagamine, Tetsuya Kaneko, Hideo Sakane, Tadashi Okano, Yutaka Yoshioka, Shigeyoshi Tsuji, Hiroki Wakabayashi, Yuya Takakubo, Toki Takemoto, Takayoshi Fujibayashi, Tatsuo Watanabe, Takefumi Kato, Hajime Ishikawa, Yoshihisa Nasu, Eiji Torikai, Atsushi Kaneko, Hideki Takagi, Toshifumi Fujiwara, Daisuke Kihira, Kyosuke Hattori, Kenji Kishimoto, Yoshifumi Ohashi, Yasumori Sobue, Yutaka Yokota, Tsuyoshi Nishiume, Kenya Terabe, Nobunori Takahashi, Masayo Kojima, Shiro Imagama, Toshihisa Kojima
Publikováno v:
Journal of Orthopaedic Science.
Autor:
Daisuke Suzuki, Eiji Torikai
Publikováno v:
Poster Presentations.
Background: Baricitinib (bari) is approved for treating moderate–severe rheumatoid arthritis (RA) in many countries, including Japan. Bari is an oral Janus kinase (JAK1)/JAK2 selective inhibitor and has shown good efficacy in RA and an adequate res
Autor:
Daisuke Suzuki, Eiji Torikai
Publikováno v:
Poster Presentations.
Background: Baricitinib (bari) is approved for treating moderate-severe RA in many countries including Japan. Bari, an oral Janus kinase (JAK1)/JAK2 selective inhibitor, has shown the efficacy in patients with rheumatoid arthritis (RA) and in adequat
Autor:
Daisuke Suzuki, Eiji Torikai
Publikováno v:
Poster Presentations.
Background: Baricitinib (bari) is approved for treating moderate–severe rheumatoid arthritis (RA) in many countries, including Japan. Bari is an oral Janus kinase (JAK1)/JAK2 selective inhibitor that has shown good efficacy in patients with RA and
Autor:
Noriyoshi Ogawa, Takafumi Naito, Junya Ohshiro, Hikaru Sato, Eiji Torikai, Motohiro Suzuki, Junichi Kawakami
Publikováno v:
Clinical biochemistry. 69
Background This study aimed to evaluate the relationships between concomitant biologic disease-modifying anti-rheumatic drugs (DMARDs) and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthr
Publikováno v:
Clinical Rheumatology. 26:1088-1093
Rheumatoid arthritis (RA) is an autoimmune disease characterized by infiltration of lymphocytes, macrophages, and plasma cells into synovial membrane. The chemokines family promotes chemotactic activity in various leukocyte cell types. Chemokines thu
Publikováno v:
Rheumatology International. 27:467-472
The aim of this study was to analyze the change of serum chemokins levels of CXCL16, CX3CL1/Fractalkine, and CXCL10/interferon-gamma inducible protein-10 (IP-10) with rheumatoid arthritis (RA), by infliximab treatment. The effects of infliximab treat
Publikováno v:
Modern rheumatology. 22(1)
To investigate the role of interleukin (IL)-33 in rheumatoid arthritis (RA) patients, we measured the serum levels of IL-33 in RA patients before and after the administration of etanercept. Twenty-four patients with RA were treated with etanercept. C
Publikováno v:
Sports Medicine, Arthroscopy, Rehabilitation, Therapy & Technology, Vol 2, Iss 1, p 25 (2010)
Sports Medicine, Arthroscopy, Rehabilitation, Therapy & Technology: SMARTT
Sports Medicine, Arthroscopy, Rehabilitation, Therapy & Technology: SMARTT
Arthroscopic partial menisectomy followed by cyst decompression is currently recommended for treatment of a meniscal cyst. However, it is doubtful whether partial menisectomy should be performed on cysts communicating with the joint in cases without
Autor:
Yasunori Kageyama, Yukio Koide, Susumu Terakawa, Akira Nagano, Eiji Kohno, Toru Hirano, Eiji Torikai
Publikováno v:
Clinical rheumatology. 27(6)
We investigated the efficacy of photodynamic therapy (PDT) using talaporfin sodium as a new method of synovectomy for rheumatoid arthritis (RA). We first used RA synovial membrane (RASM) for in vitro and in vivo study. The RASM was obtained from pati